Device Trial Radar · NCT06035523
Clinical Study Evaluating Wound Closure With Endoform™ and Symphony™
Last checked: Nov 20, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Dec 29, 2021
Primary completion
Aug 30, 2025
Study completion Aug 30, 2025
Sponsor
- Lead sponsor
- Aroa Biosurgery LimitedNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Professional Education and Research Institute
- First posted
- Sep 13, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study will evaluate the performance and safety of Endoform™ Natural and Endoform™ Antimicrobial in conjunction with Symphony™ in the treatment of chronic non-healing diabetic foot ulcers after 12 weeks of treatment.
Conditions
- Wound Healing
- Diabetic Foot
- Chronic Foot Ulcer
- Foot Ulcer
Interventions
Endoform™ AntibacterialDevice
Application of Endoform™ Antibacterial
Endoform™ NaturalDevice
Application of Endoform™ Natural
Symphony™Device
Application of Symphony™
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of index ulcers (the ulcers being treated in the study) healed at 12 weeksTime frame: 12 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
South Florida Lower Extremity Center
Hollywood, Florida
Advanced Pharma Cr, LLC
Miami, Florida
Foot and Ankle Specialists of the Mid-Atlantic
Salem, Virginia
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.